Identification of tetragocarbone C and sideroxylin as the most potent anti-inflammatory components of Syncarpia glomulifera

Quality assessment and chemical diversity of Australian propolis from Tetragonula carbonaria and Tetragonula hockingsi stingless bees

Stingless bee propolis has gained global attention as a novel source of bioactive compounds with potential applications in food and medicine to promote human health. However, research on Australian stingless bee propolis remains limited as much of propolis is discarded by Australian beekeepers due to a lack of understanding its value. This study aimed to assess and compare the quality and chemical diversity of propolis from two Australian stingless bee species Tetragonula carbonaria and Tetragonula hockingsi across Queensland and New South Wales. Chemical assays revealed that T. hockingsi propolis had significantly higher total phenolic and flavonoid contents than T. carbonaria. Australian stingless bee propolis also showed high phenolic but moderate flavonoid content compared to international propolis sources. The phenolic content displayed geographical dependence, decreasing from northern to southern regions. The analyses of uHPLC-QTOF MS and 1H NMR profiling identified nine distinct propolis types, showcasing diverse chemical composition with the presence of flavan-3-ol, dihydroflavonol, flavanone, tannin, lignan, phenolic acid, cinnamic acid glycoside, chalcone, and alkyl-phenylketone compounds. These findings provide a foundation for future research into the value and therapeutic potential of Australian stingless bee propolis products, contributing to the development of the Australian propolis industry.

Exploring the Anti-Inflammatory Potential of Australian Native Plants Based on their Ethnopharmacological Knowledge

Inflammation represents the inherent protective reaction of the human body to various harmful agents and noxious stimuli. Standard anti-inflammatory therapy including nonsteroidal anti-inflammatory drugs are associated with several side effects. In the past decades, people rely on medicinal plants for the treatment of inflammation. The traditional utilization of medicinal plants is regarded as a safe, cost-effective, and broadly accepted approach. In this study, anti-inflammatory activity of plants traditionally utilized by the D'harawal people in Australia has been assessed in vitro. Eighty Australian native plants were screened based on the Dharawal Pharmacopeia for their inhibitory effect on the nitric oxide (NO) production in lipopolysaccharides (LPS) and interferon (IFN)-γ stimulated RAW 264.7 murine macrophages for their anti-inflammatory activity. From the eighty ethanolic extracts screened, seventeen displayed potent NO inhibition with an IC50 recorded below 15 μg/mL. The aim of this review was to utilise the ethnopharmacological knowledge and to correlate the anti-inflammatory activity of the seventeen plants with either their known or unknown phytochemicals reported in the literature. In doing so, we have created a snapshot of Australian native plant candidates that warrant further chemical investigation associated with their anti-inflammatory activity.

From the Bush to the Brain: Preclinical Stages of Ethnobotanical Anti-Inflammatory and Neuroprotective Drug Discovery-An Australian Example

The Australian rainforest is a rich source of medicinal plants that have evolved in the face of dramatic environmental challenges over a million years due to its prolonged geographical isolation from other continents. The rainforest consists of an inherent richness of plant secondary metabolites that are the most intense in the rainforest. The search for more potent and more bioavailable compounds from other plant sources is ongoing, and our short review will outline the pathways from the discovery of bioactive plants to the structural identification of active compounds, testing for potency, and then neuroprotection in a triculture system, and finally, the validation in an appropriate neuro-inflammatory mouse model, using some examples from our current research. We will focus on neuroinflammation as a potential treatment target for neurodegenerative diseases including multiple sclerosis (MS), Parkinson's (PD), and Alzheimer's disease (AD) for these plant-derived, anti-inflammatory molecules and highlight cytokine suppressive anti-inflammatory drugs (CSAIDs) as a better alternative to conventional nonsteroidal anti-inflammatory drugs (NSAIDs) to treat neuroinflammatory disorders.

Clinical Relevance and Tumor Growth Suppression of Mitochondrial ROS Regulators along NADH:Ubiquinone Oxidoreductase Subunit B3 in Thyroid Cancer

Mitochondrial reactive oxygen species (mitoROS) are a double-edged sword in cancer progression, connoting the ROS-dependent malignant transformation and the oxidative stress-induced cell death. However, the underlying role of mitoROS in thyroid cancer remains unclear. Here, we collected 35 prominent mitoROS regulators to stratify 510 thyroid cancer patients in TCGA cohort through consensus clustering. Three molecular subtypes (cluster 1/2/3) were identified, among which cluster 1 (mitoROSlow) was preferentially associated with unfavorable prognosis. Individually, there were 12 regulators with a high expression that predicted a significantly favorable progression-free survival. The NADH:Ubiquinone Oxidoreductase Subunit B3 (NDUFB3) had a highest impact. NDUFB3 knockdown significantly reduced mitoROS levels in BCPAP and C643 cells. Bioinformatically, the consistency between NDUFB3 expression and cluster 1/2/3 was confirmed; lower expression of NUDFB3 was associated with a poor clinical outcome. Pathway analysis of differentially expressed genes in the NDUFB3low and NDUFB3high cohorts revealed a predominance of oxidative phosphorylation pathway changes. Consistently, mitochondrial functions, including oxygen consumption rate, ATP levels, complex I activity, mitoROS levels, and the expression of mitochondrially encoded NADH:Ubiquinone oxidoreductase core subunit 5, were significantly increased in NDUFB3-overexpressed BCPAP cells or C643 cells. The in vivo NDUFB3 overexpression and sideroxylin treatment significantly suppressed tumor growth and prolonged survival, concurrently elevating mitoROS levels ex vivo in mouse xenograft models. Conversely, NDUFB3 knockdown had the opposite effect. Together, these findings implicated the importance of mitoROS regulators in predicting clinical outcomes of patients with thyroid cancer. Our findings may pave the way for developing a mitoROS-based treatment for thyroid cancer patients.